Healthcare Delivery Venture Capital: Why Closing the Last Mile Creates Value

Medicine can discover a better drug, build a more accurate diagnostic, or train a more capable clinical model and still fail at the final step: getting the right intervention to the right person at the right time.

Presented By Our Partners

That final step is healthcare delivery. It includes the ordinary, difficult work between scientific possibility and an improved human outcome—finding a clinician, obtaining coverage, coordinating specialists, scheduling treatment, supporting adherence, monitoring recovery, and knowing whether the intervention actually worked.

For venture investors, delivery is attractive because the problems are enormous and recurring. It is dangerous for the same reason. A company can create genuine clinical value while being crushed by labor costs, reimbursement friction, slow sales cycles, weak patient retention, or dependence on a single payer or health-system customer.

The best healthcare-delivery businesses do more than place a digital front door on an old system. They redesign the path of care and prove that the new path is clinically sound, operationally repeatable, and economically durable.

A broader view of healthcare venture capital connects this delivery challenge with the emerging economics of durable healthcare AI moats and generative biology.

The Last Mile Is Where Healthcare Becomes Real

Healthcare delivery is often treated as the less glamorous end of innovation. Discovery produces the molecule. Engineering produces the device. Artificial intelligence produces the recommendation. Delivery determines whether any of it changes a life.

The category spans:

• primary and specialty care;
• virtual and hybrid clinics;
• home-based care;
• chronic-disease management;
• behavioral health;
• care navigation and coordination;
• pharmacy and medication support;
• post-acute and rehabilitation services;
• remote monitoring;
• clinical workflow infrastructure;
• and services that move care into lower-cost settings.

These businesses sit directly inside the constraints of the American healthcare system. Payment is fragmented. Clinical responsibility is distributed across organizations. Patients change insurance. Data arrives late or not at all. A workflow that saves time for one participant may create work for another.

That complexity creates opportunity, but it also means that convenience alone is rarely a moat.

Why Delivery Is an Investment Category Now

Several structural pressures are converging.

First, the population is older and more medically complex. Chronic conditions require longitudinal management rather than a single encounter. Second, clinician capacity is constrained, making labor productivity and better team design essential. Third, patients increasingly expect access outside the traditional hospital or office visit. Fourth, public and private payers are looking for ways to connect payment more closely to quality, outcomes, and total cost.

The Centers for Medicare & Medicaid Services describes value-based care as a model in which providers are evaluated on quality and individual health outcomes rather than volume alone. Its 2025 Innovation Center strategy emphasizes evidence-based prevention, patient empowerment, and greater choice and competition. Those priorities favor companies that can improve care while producing credible evidence about cost and outcomes.

The financial pressure is equally important. Hospitals, physician groups, and health plans do not buy technology in a vacuum. They buy solutions to capacity, cost, quality, access, and revenue problems. A delivery company that cannot identify which operating budget it improves—and how quickly—will struggle even if clinicians like the product.

Five Places Venture-Scale Value Can Form

1. Access

Access businesses help patients find and reach appropriate care. The obvious metric is appointment volume, but the more important question is whether the service resolves a meaningful clinical need.

A virtual visit that ends with an unnecessary emergency-department referral has moved the queue, not solved the problem. A navigation service that sends patients to an in-network, clinically appropriate provider and closes the follow-up loop has created more durable value.

Strong access models improve time to treatment, reduce avoidable leakage, and reach people whom the existing system serves poorly.

2. Care redesign

Care-redesign companies change who performs the work, where it happens, and how the team collaborates. A physician may be supported by nurses, pharmacists, coaches, community health workers, or software that removes clerical tasks and highlights the cases requiring human judgment.

The aim is not to replace clinicians indiscriminately. It is to reserve scarce expertise for the work that needs it while standardizing everything that can safely be standardized.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The strongest models show that the redesigned pathway maintains or improves quality. Without that proof, lower cost may simply mean less care.

3. Longitudinal relationships

Healthcare value often appears over months or years. Diabetes, hypertension, heart failure, obesity, behavioral health, and complex specialty conditions cannot be reduced to a sequence of disconnected visits.

Longitudinal models can develop richer data, better adherence, and stronger patient trust. They can also suffer from high acquisition costs and rapid disengagement. Registration is not retention, and retention is not a clinical outcome.

Investors should look for evidence that patients remain engaged because the service is useful, not because an employer or plan temporarily subsidizes it.

4. Movement into the home and community

Home health, hospital-at-home programs, remote monitoring, mobile diagnostics, infusion, and community-based services can move care closer to daily life. The potential advantages include convenience, lower facility costs, and a more accurate view of how a person functions outside a clinic.

But the home is not a frictionless care setting. Companies must coordinate staffing, logistics, equipment, escalation, safety, and reimbursement across a dispersed geography. Density matters. A model that works in one metropolitan area may deteriorate when travel time and workforce availability change.

MedPAC reported that about 2.7 million fee-for-service Medicare beneficiaries received home healthcare in 2023 and that Medicare spent $15.7 billion on those services. The scale is real; so are the operational and policy dependencies.

5. The operating layer

Some of the most defensible delivery companies do not own the patient relationship. They provide the infrastructure that makes other care organizations work better: scheduling, clinical documentation, revenue-cycle support, referral management, prior authorization, workforce orchestration, or measurement.

The danger is becoming another point solution inside an already crowded technology stack. The opportunity is to own a critical workflow, integrate deeply, and create measurable improvement in labor, throughput, revenue, quality, or risk.

This is where artificial intelligence can matter most. A model embedded in a high-frequency workflow can reduce administrative burden or improve decisions. A model that produces an impressive answer but does not fit the care process remains a demonstration.

The Business Models—and Their Hidden Risks

Healthcare-delivery companies commonly earn revenue through several structures.

Fee for service pays for each visit or procedure. It is familiar and can produce immediate revenue, but it may reward volume rather than better outcomes.

Per-member-per-month contracts pay a recurring fee for access or management. They improve revenue visibility, but margins depend on enrollment, utilization, staffing, and whether the company is responsible for care that patients do not use.

Shared savings and risk contracts reward improvements in total cost and quality. They can create powerful alignment, but attribution, benchmarks, patient churn, coding, and claims lag make performance difficult to measure.

Employer contracts can open distribution quickly. They also expose a company to long benefit cycles, broker influence, concentration, and the possibility that utilization does not support renewal.

Health-plan or health-system contracts can provide scale and credibility. Sales and implementation are slow, integrations are demanding, and the customer may hold substantial negotiating power.

Direct-to-consumer care offers speed and control over the brand. It also requires continuous acquisition spending and creates a hard test: will people pay when the advertising stops?

Many companies blend these models. The important diligence question is not what the contract is called. It is who pays, what result the buyer expects, how that result is measured, and which party carries clinical and financial risk.

The Evidence Ladder for Healthcare Delivery

Delivery businesses should be evaluated through an evidence ladder.

1. Demand: patients, clinicians, or buyers clearly want the service.
2. Engagement: people use it beyond the first encounter.
3. Operational performance: the model delivers care reliably with acceptable wait times, staffing, and escalation.
4. Clinical quality: outcomes and safety are at least comparable to the alternative.
5. Economic value: the service reduces avoidable cost, increases appropriate revenue, or improves labor productivity.
6. Reproducibility: performance survives expansion across populations, markets, and customers.
7. Durability: retention, reimbursement, and margins remain sound after incentives and pilot support fade.

Companies often emphasize the first two levels because they are faster to measure. Venture-scale healthcare value becomes more credible as evidence moves upward.

What the Unit Economics Must Reveal

Software investors often focus on gross margin and recurring revenue. Those metrics matter in care delivery, but they can mislead when clinical labor is classified inconsistently or important costs sit outside the apparent service margin.

Useful diligence separates:

• customer acquisition from patient activation;
• enrolled members from active patients;
• visit contribution margin from total program margin;
• fixed clinical capacity from variable utilization;
• implementation revenue from recurring revenue;
• reported savings from independently validated savings;
• and growth created by subsidies from growth created by lasting demand.

Labor productivity deserves special attention. If every new patient requires a proportional increase in expensive clinical staff, the company may be a good provider without becoming a venture-scale business. Technology must either improve the productivity of the care team, shift work safely, increase retention, or support better economics in another measurable way.

Risk-bearing businesses require an additional layer of analysis. A company can appear profitable before claims mature or before a high-cost subgroup is fully represented. Cohort age, risk adjustment, stop-loss protection, and claims completion can change the result dramatically.

The Most Important Diligence Questions

Investors evaluating a healthcare-delivery company should ask:

1. What specific failure in the existing care pathway does the company fix?
2. Who experiences the value, and who writes the check?
3. Is the service clinically necessary, merely convenient, or both?
4. What evidence shows that patients remain engaged and improve?
5. Which costs are genuinely removed rather than shifted elsewhere?
6. How much clinical labor is required for the next thousand patients?
7. What happens when utilization is higher or lower than forecast?
8. Which reimbursement, licensing, or scope-of-practice rules affect expansion?
9. Can the model work outside its founding geography or anchor customer?
10. What does the company know from its workflow and outcomes data that competitors cannot easily recreate?
11. Is artificial intelligence improving a real operating metric or decorating the pitch?
12. Will the next financing resolve a decisive clinical, economic, or scaling risk?

The final question prevents capital from funding motion without learning. A delivery company should become easier to underwrite after each financing round, not merely larger.

Where Durable Moats Form

The strongest healthcare-delivery moats usually combine several elements:

• trusted patient or clinician relationships;
• distribution embedded in benefits, provider networks, or referral pathways;
• multistate clinical and regulatory operations;
• proprietary longitudinal workflow and outcomes data;
• deep integration into clinical and administrative systems;
• demonstrated quality and economic results;
• contracting capability across payers and risk models;
• and local operating density where physical services are required.

Brand alone is rarely sufficient. Neither is software alone. The moat forms when data, workflow, distribution, evidence, and operations reinforce one another.

Closing the Last Mile

Healthcare delivery is where innovation meets constraint. It is also where enormous value can be created. A better pathway can prevent deterioration, reduce avoidable hospitalization, return time to clinicians, expand access, and turn a scientific advance into an outcome that matters.

The investable companies will not merely add another interface between patients and a fragmented system. They will remove fragmentation. They will show who benefits, who pays, what improves, and why the result can be repeated.

In healthcare venture capital, the last mile is not the final administrative detail. It is the product.

For those following the affiliated investment initiative, Healthcare Venture Capital Fund is developing a healthcare-focused, deal-by-deal investment platform. Healthcare Venture Capital Fund and HealthcareDiscovery.ai are affiliated projects; this reference is informational and is not an offer, solicitation, or investment recommendation.

Sources and Further Reading

• Centers for Medicare & Medicaid Services, Value-Based Care.
• CMS Innovation Center, 2025 Strategic Direction.
• CMS Innovation Center, Overview.
• MedPAC, June 2025 Report to the Congress: Medicare and the Health Care Delivery System.
• MedPAC, Home Health Care Services, March 2025.
• American Hospital Association, The Cost of Caring.

This article is for informational and educational purposes only. It does not constitute investment, legal, tax, or medical advice, an offer to sell securities, or a solicitation to purchase any investment.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.